Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Herantis Pharma Plc | Company release | 2 July 2024 at 8:45 a.m.
Herantis Pharma Plc's board decides on new option rights program for managing director, management team and other key personnel
The Board of Directors of Herantis Pharma Plc ("Herantis") has on 2 July 2024 decided on a new option rights program 2024 I. Under the new option rights program 2024 I, in aggregate up to 400,000 option rights entitling to shares may be issued to the CEO of Herantis, management team members, and other key personnel. The new option rights program is based on the authorization granted by the Annual General Meeting held on 24 April 2024. There is a weighty financial reason to issue the option rights as they will be offered to management team members and other key personnel to increase their commitment towards long-term contribution to growing shareholder value in Herantis.
The option rights will be offered without consideration. Each option right entitles to subscribe for one new ordinary share in Herantis. The share subscription price is 126% of the volume weighted average share price during 10 trading days preceding the grant date of the option rights.
Granted share options shall vest and become exercisable over a three-year period, with 1/3 becoming exercisable one year after the grant date, with an annual vesting of 1/3 during the second year after the grant date, and with an annual vesting of 1/3 during the third year after the grant date. The options expire five years after the grant date or earlier subject to customary conditions.
Any shares to be subscribed for based on the option rights of the program 2024 I will not represent more than 10% of the company's outstanding shares at any time.
Herantis Pharma Plc
The Board of Directors
For more information, please contact:
Herantis Pharma Plc, Timo Veromaa, Chair of the Board of Directors, telephone: +358 40 5739933
Email: ir@herantis.com
---------------------------------
Certified Advisor:
UB Corporate Finance Ltd
Tel.: +358 9 25 380 225
E-mail: ubcf@unitedbankers.fi
About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson's disease. Herantis' lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Company website: www.herantis.com